Comparative absorption profiles of divalproex sodium delayed-release versus extended-release tablets - Clinical implications

Annals of Pharmacotherapy

Volumn 40, Issue 4, 2006, Pages 619-625

  Dutta, Sandeep ^a   Reed, Ronald C ^a   O'Dea, Robert F ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Absorption; Delayed release; Extended release; Pharmacokinetics; Sustained release; Valproate; Valproic acid: Controlled release

Indexed keywords

VALPROATE SEMISODIUM;

ADULT; ARTICLE; COMPARTMENT MODEL; CONTROLLED DRUG RELEASE; CONTROLLED RELEASE FORMULATION; DELAYED DRUG RELEASE; DELAYED RELEASE FORMULATION; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG FORMULATION; FEMALE; HUMAN; MALE; NORMAL HUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; SUSTAINED DRUG RELEASE; SUSTAINED RELEASE PREPARATION; TABLET FORMULATION;

ABSORPTION; ADULT; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; MALE; TABLETS, ENTERIC-COATED; TIME FACTORS; VALPROIC ACID;

EID: 33646251411     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1G617     Document Type: Article

References (24)

1. Wilder BJ, Karas BJ, Penry JK, Asconape J. Gastrointestinal tolerance of divalproex sodium. Neurology 1983;33:808-11.
2. Dutta S, Reed RC, Cavanaugh JH. Absolute bioavailability and absorption characteristics of divalproex sodium extended-release tablets in healthy volunteers. J Clin Pharmacol 2004;44:737-42.
3. Dutta S, Reed RC, Cavanaugh JH. A multiphasic absorption model for characterizing single dose pharmacokinetics of divalproex-ER in healthy subjects (abstract). Clin Pharmacol Ther 2005;77:P33.
4. Package insert. Depakote (divalproex sodium delayed-release tablets). North Chicago, IL: Abbott Laboratories, September 2004.
5. Dutta S, Cloyd JC, Granneman GR, Collins SD. Oral/intravenous maintenance dosing of valproate following intravenous loading: a simulation. Epilepsy Res 2003;53:29-38.
6. Reed RC, Dutta S. What is the best strategy for converting from twice-daily divalproex to a once-daily divalproex ER regimen?: examinations and answers via computer simulations. Clin Drug Invest 2004;24:509-21.
7. Reed RC, Dutta S. Predicted serum valproic acid concentrations in patients missing and replacing a dose of extended-release divalproex sodium. Am J Health Syst Pharm 2004;61:2284-9.
8. Pellock JM, Smith MC, Cloyd JC, Uthman B, Wilder BJ. Extended-release formulations: simplifying strategies in the management of anti-epileptic drug therapy. Epilepsy Behav 2004;5:301-7.
9. Doughty J, Baker GA, Jacoby A, Lavaud V. Compliance and satisfaction with switching from an immediate-release to sustained-release formulation of valproate in people with epilepsy. Epilepsy Behav 2003;4:710-6.
10. Qiu Y, Cheskin HS, Engh KR, Poska RP. Once-a-day controlled-release dosage form of divalproex sodium I: formulation design and in vitro/in vivo investigations. J Pharm Sci 2003;92:1166-73.
11. Dutta S, Zhang Y, Selness DS, et al. Comparison of the bioavailability of unequal doses of divalproex sodium extended-release formulation relative to the delayed-release formulation in healthy volunteers. Epilepsy Res 2002;49:1-10.
12. Sommerville KW, Dutta S, Biton V, et al. unavailability of a divalproex sodium extended-release formulation versus divalproex sodium delayed-release tablet formulation in adult patients on enzyme-inducing antiepileptic drugs. Clin Drug Invest 2003;23:661-70.
13. Dutta S, Reed RC. Divalproex to divalproex extended release conversion. Clin Drug Invest 2004;24:495-508.
14. Dutta S, Zhang Y. Bioavailability of divalproex extended-release formulation relative to the divalproex delayed-release formulation. Biopharm Drug Dispos 2004;25:345-52.
15. Davis SS, Hardy JG, Fara JW. Transit of pharmaceutical dosage forms through the small intestine. Gut 1986;27:886-92.
16. Madsen JL. Effects of gender, age, and body mass index on gastrointestinal transit times. Dig Dis Sci 1992;37:1548-53.
17. Argenyi EE, Soffer EE, Madsen MT, Berbaum KS, Walkner WO. Scintigraphic evaluation of small bowel transit in healthy subjects: inter- and intrasubject variability. Am J Gastroenterol 1995;90:938-42.
18. Degen LP, Phillips SF. Variability of gastrointestinal transit in healthy women and men. Gut 1996;39:299-305.
19. Fischer JH, Barr AN, Paloucek FP, Dorociak JV, Spunt AL. Effect of food on the serum concentration profile of enteric-coated valproic acid. Neurology 1988;38:1319-22.
20. Zhou H. Pharmacokinetic strategies in deciphering atypical drug absorption profiles. J Clin Pharmacol 2003;43:211-27.
21. Smith MC, Centorrino F, Welge JA, Collins MA. Clinical comparison of extended-release divalproex versus delayed-release divalproex: pooled data analyses from nine trials. Epilepsy Behav 2004;5:746-51.
22. Wassef AA, Winkler DE, Roache AL, et al. Lower effectiveness of divalproex versus valproic acid in a prospective, quasi-experimental clinical trial involving 9,260 psychiatric admissions. Am J Psychiatry 2005;162:330-9.
23. Freitag FG, Collins SD, Carlson HA, et al. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology 2002;58:1652-9.
24. Thibault M, Blume WT, Saint-Hilaire JM, et al. Divalproex extended-release versus the original divalproex tablet: results of a randomized, crossover study of well-controlled epileptic patients with primary generalized seizures. Epilepsy Res 2002;50:243-9.